GlassScriptPhysician profile
Austin Jeffrey Gillette
NPI 1750918272
$1,595.93
in general payments reported to CMS, 2019-2025
23 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $281 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.12 | 2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $171.04 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $164.13 | 2025 | |
| Glaxosmithkline, LLC. | $149.66 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $125.77 | 2024-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.88 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $95.34 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $79.16 | 2024-2025 | |
| Shield Therapeutics INC | $60.92 | 2025 | |
| Sumitomo Pharma America, INC. | $45.38 | 2025 | Gemtesa |
| Exact Sciences Corporation | $44.04 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.62 | 2025 | |
| Merck Sharp & Dohme LLC | $36.92 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.09 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $29.70 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $27.36 | 2025 | |
| Dynavax Technologies Corporation | $26.59 | 2025 | Heplisav-B |
| Daiichi Sankyo INC. | $24.86 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $22.40 | 2024 | Voquezna |
| Boston Scientific Corporation | $20.34 | 2025 | General - Pain Management |
| Abbott Laboratories | $18.21 | 2025 | Freestyle Libre 3 |
| Ascensia Diabetes Care US INC. | $15.47 | 2025 | |
| Cranial Technologies, INC | $13.93 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Gillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.